Independent · Evidence-led · We don't sell peptides
EU / NordicsUpdated weeklyEN
#Deep dive
Long-form pieces over 2,000 words.
Explainer
Tirzepatide history: discovery to approval
Six milestones trace how tirzepatide went from a laboratory dual-agonist hypothesis in 2018 to one of the most-studied prescription medicines in the world.
Explainer
Tesamorelin: from discovery to FDA approval
How tesamorelin moved from a lab compound to FDA approval in 2010, and why the European application was withdrawn in 2012.
Explainer
A short history of TB-500
TB-500 (thymosin beta-4) was first sequenced in 1981. Four decades on, it has no approved human use and only one controlled trial, in eye disease.
Explainer
Semax: from 1991 lab bench to today
Semax is licensed in Russia for stroke recovery but unapproved in the West. Here is how it got from a Moscow lab in 1991 to today's grey market.
Explainer
Ipamorelin history: discovery to today
Ipamorelin was first characterised at Novo Nordisk in 1998. Here is the research timeline and why no approved medicine followed.